Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT04965545
Recruiting Observational

Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease

NCT04965545 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Observational
Started
2004-01-01
Last updated
2021-07-16

Condition(s) studied

Wilson Disease

Investigational drug(s) / intervention(s)

low copper diet

low copper diet: All patients with wilson disease should receive low copper diet

Study summary

The investigators aimed to identify factors associated with symptoms and features of Wilson disease from a large cohort during long-term follow-up

Eligibility

Sex
ALL
Min age
6 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * genetically diagnosed patients with wilson disease Exclusion Criteria: * Deny follow-up

Primary outcome measure(s)

  • Serum ceruloplasmin — From 2004 through 2030
    Serum ceruloplasmin levels were collected among patients with wilson disease. After confirming a non-Gaussian distribution, the reference range of serum ceruloplasmin level was determined.
  • Urinary Copper Excretion — From 2004 through 2030
    The measurement of 24-hour urine copper excretions were collected and measured.
  • Kayser-Fleischer Rings — From 2004 through 2030
    The presence of Kayser-Fleischer Rings among patients with wilson disease were confirmed via slit lamp.
  • Brain Magnetic Resonance Imaging — From 2004 through 2030
    Brain Magnetic Resonance Imaging of all patients were collected and analyzed.

Trial sites (1)

FacilityCityRegionStatus
Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang Recruiting

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Laparoscopic Versus Open Surgery for Colon Cancer With Visceral Obesity Recruiting
Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence Starting soon
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL Recruiting
A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps Recruiting
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer Recruiting

Other trials for the same condition

An Exploratory Study to Evaluate the Tolerability and Safety of MWAV201 in Subjects With Wilson Disease Active, not recruiting
A Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease Recruiting
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD) Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04965545 on ClinicalTrials.gov ↗ ← All trials in China